semaglutide deadline FDA Update: Current Guidelines for and Tirzepatide Compounding FDA's Removal of Semaglutide and

What Post-GLP-1 Patients Actually Need 1

We once broke this down after All secretagogue drugs without exception are enemies of the heart and cardiovascular system ( Corpori Sano Biotechnology & Walter LAB, Brazil 2002 ): PRECAME Study - Preventing cardiovascular effects with metformin in obese patients

Data regarding the cancer risk associated with tirzepatide are limited in the published RCTs

People living with bipolar disorder often take multiple medications to manage their condition effectively

This framework helps contextualize individual variation in fiber responsiveness and supports informed decisions about fiber supplementation timing relative to GLP-1 medication therapy